Back to search resultsSummaryRMgm-842
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23356439 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Lindner SE; Kappe SH |
Name Group/Department | Seattle Biomedical Research Institute |
Name Institute | Seattle Biomedical Research Institute |
City | Seattle |
Country | US |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-842 |
Principal name | pypuf2- |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of salivary gland sporozoites. Sporozoites progressively lost infectivity after arrival in the salivary glands, becoming non-infectious within the following 8 days. A significant and progressively increasing fraction of sporozoites prematurely transformed inside the salivary glands into forms that resemble young liver stages |
Liver stage | Normal numbers of salivary gland sporozoites. Sporozoites progressively lost infectivity after arrival in the salivary glands, becoming non-infectious to mice within the following 8 days. |
Additional remarks phenotype | Mutant/mutation |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_0719200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0417100 | ||||||||||||||||||||||||
Gene product | mRNA-binding protein PUF2 | ||||||||||||||||||||||||
Gene product: Alternative name | Pumilio2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | Gene targeting constructs for transgenic parasite production were designed as previously described with some modifications (Mikolajczak et al., 2008a). Briefly, two regions of the targeted locus were PCR amplified. The two PCR products were fused by Sequence Overlap Extension PCR (“SOE PCR”) by virtue of complementary sequences designed into the primers. This SOE PCR product (“targeting sequence”) was digested at the 5’ and 3’ ends via exogenous restriction sites designed in the primers and inserted into a modified pDEF vector designed for genetic disruptions or for gene modifications by locus replacement via double-crossover recombination. Prior to transfection, plasmids were linearized at unique restriction sites designed between the two halves of the targeting sequences | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |